Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00951054 · ClinicalTrials.gov registry record · Phase 2

A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer

A Phase 2 study, sponsored by Nippon Kayaku Co..

Completed
Registry status
Phase 2
Development phase
61
Enrollment target

NCT00951054 is a Phase 2 study that has completed, run by Nippon Kayaku Co.. The registered enrollment target is 61 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00951054, a Phase 2 study, has completed, sponsored by Nippon Kayaku Co..

COMPLETED
Registry status
Phase 2
Development phase
61 participants
Enrollment target

Study Summary

The purpose of this study is to determine whether NK012 is safe and effective in the treatment of advanced and metastatic triple negative breast cancer.

Interventions

  • DRUG NK012

Trial Details

FieldValue
Enrollment Target 61 participants
Start Date 2009-02
Est. Completion 2015-02
Phase Phase 2

Sponsor

Nippon Kayaku Co.

5 total trials

What the Registry Record Tells You About NCT00951054

The ClinicalTrials.gov registry entry for NCT00951054 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 61 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nippon Kayaku Co., which has 5 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which NK012 is the first listed.

NCT00951054 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00951054 about?

NCT00951054 is a clinical study titled "A Study of NK012 in Patients With Advanced, Metastatic Triple Negative Breast Cancer". The purpose of this study is to determine whether NK012 is safe and effective in the treatment of advanced and metastatic triple negative breast cancer.

What is the current status of trial NCT00951054?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 61 participants. The study started on 2009-02. Estimated completion is 2015-02.

What interventions are being tested in trial NCT00951054?

The interventions under investigation include: NK012 (DRUG).

Who is sponsoring clinical trial NCT00951054?

This trial is sponsored by Nippon Kayaku Co., which has 5 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.